Longevity + SkinResearch-onlyAnimal / preclinicalUpdated 2026-04-24

Peptide reference file

KPV

Trending #13 in Longevity8.4k searches/moHyped

KPV is a short alpha-MSH-derived peptide fragment discussed in inflammation, barrier, skin, and gut-support contexts.

Current readout: animal / preclinical evidence, research-only status, not approved approval state, human evidence is not established here, no linked trial record is attached yet, and 3 linked sources in the seed trail.

PubChem CID 13294447 | 180 PubMed results | 4 trial records | 0 DailyMed labels | 0 Drugs@FDA applications

KPV is mostly discussed because it is appealing because it sounds like a small, simple peptide with both skin and gut relevance.

The public claim is straightforward: It is appealing because it sounds like a small, simple peptide with both skin and gut relevance. Mostly preclinical signal with growing interest in skin and gut discussions.

In plain language, kPV is a short alpha-MSH-derived peptide fragment discussed in inflammation, barrier, skin, and gut-support contexts.

Animal / preclinicalResearch-only
Inflammation discussionBarrier supportSkin and gut context

Aliases: Lys-Pro-Val, alpha-MSH fragment KPV

SpecimenKPV specimen
CCCCCCHHHHHHHOO
Formula
C11H12O3
Mass
192.21
Evidence
Animal / preclinical
Elements
3

Most commonly discussed in relation to Inflammation discussion, Barrier support, Skin and gut context.

What KPV is

KPV is a short alpha-MSH-derived peptide fragment discussed in inflammation, barrier, skin, and gut-support contexts.

KPV is grouped under Longevity + Skin / Fitness + Recovery on PeptideFactCheck because it is appealing because it sounds like a small, simple peptide with both skin and gut relevance.

The useful starting point is to separate the molecule itself from the internet story around it. It is appealing because it sounds like a small, simple peptide with both skin and gut relevance.

Why people keep looking it up

It is appealing because it sounds like a small, simple peptide with both skin and gut relevance.

KPV is a short alpha-MSH-derived peptide fragment discussed in inflammation, barrier, skin, and gut-support contexts.

KPV tends to stay in the conversation because it touches a familiar public theme: inflammation discussion, barrier support, and skin and gut context. That makes it easy for the claim to travel faster than the evidence.

What the evidence can support right now

Mostly preclinical signal with growing interest in skin and gut discussions.

Direct human evidence remains limited for the broad product claims seen online.

Most support comes from preclinical inflammation and barrier-function work.

Why this page carries the current tier: Mostly preclinical signal with growing interest in skin and gut discussions.

The current seed trail for KPV is pulling from 1 literature source, 1 trials source, and 1 databases source.

Safety, limits, and regulatory context

Short-peptide simplicity can make claims sound cleaner than the evidence really is.

No FDA-approved KPV therapy is represented in this seed set.

Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for KPV. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.

Molecular and identifier data

The current PubChem match for KPV is CID 13294447. That gives the page a source-backed chemistry record rather than a placeholder identifier block.

PubChem CID
13294447
Formula
C11H12O3
Molecular weight
192.21
InChIKey
MJXXAPORLGKVLB-UHFFFAOYSA-N

Matched synonyms include 2-oxo-5-phenylpentanoic acid, 5-Phenyl-2-Keto-Valeric Acid, RefChem:537689, 88768-11-0, 2-oxo-5-phenylvaleric acid, SCHEMBL710419, 2-keto-5-phenyl-valeric acid, DB08050.

Open PubChem record

Clinical trial snapshot

The current ClinicalTrials.gov intervention query for KPV returns 4 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.

Literature snapshot

The current PubMed query for KPV returns 180 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.

Source trail

Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.

Safety noteThis content is educational only and does not replace medical advice. Peptide use may carry risks and should be discussed with a qualified medical professional.